Svenn Alexander Kommandantvold (Svenn A Hansen)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 8

Top Topics

Early Breast Cancer

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

Oncology and therapy

Expert review of pharmacoeconomics & outcomes research

Advances in therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Svenn Alexander Kommandantvold, Nikos Kotsopoulos, Isabel Monteiro, Ana Ladeiras, Andrew Hogan, Felipe Barboza Magalhães de Araujo, Mark P Connolly
Estimating Public Economic Gains from Early Breast Cancer and Curative Treatment: A Case Study in Human Epidermal Growth Factor Receptor (HER-2) Positive Targeted Therapies. Oncology and therapy (2024)
Svenn Alexander Kommandantvold, Nikos Kotsopoulos, Isabel Monteiro, Ana Ladeiras, Andrew Hogan, Felipe Barboza Magalhães de Araujo, Mark P Connolly
Estimating Public Economic Gains from Early Breast Cancer and Curative Treatment: A Case Study in Human Epidermal Growth Factor Receptor (HER-2) Positive Targeted Therapies. Oncology and therapy 12 (2) (2024)
Svenn Alexander Kommandantvold, Annabelle Lemenuel-Diot, Chris Skedgel, Richard Pitman, Peter Rouse, Hassan Zaraket, Hao Zhou, Marie-Helene Blanchet Zumofen
A cost-effectiveness analysis of reduced viral transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and pandemic influenza management in the United Kingdom. Expert review of pharmacoeconomics & outcomes research (2024)
Svenn Alexander Kommandantvold, Annabelle Lemenuel-Diot, Chris Skedgel, Richard Pitman, Peter Rouse, Hassan Zaraket, Hao Zhou, Marie-Helene Blanchet Zumofen
A cost-effectiveness analysis of reduced viral transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and pandemic influenza management in the United Kingdom. Expert review of pharmacoeconomics & outcomes research (2024)
Svenn Alexander Kommandantvold, Nikos Kotsopoulos, Isabel Monteiro, Ana Ladeiras, Andrew Hogan, Felipe Barboza Magalhães de Araujo, Mark P Connolly
Estimating Public Economic Gains from Early Breast Cancer and Curative Treatment: A Case Study in Human Epidermal Growth Factor Receptor (HER-2) Positive Targeted Therapies. Oncology and therapy 12 (2) (2024)
Svenn Alexander Kommandantvold, Nikos Kotsopoulos, Isabel Monteiro, Ana Ladeiras, Andrew Hogan, Felipe Barboza Magalhães de Araujo, Mark P Connolly
Estimating Public Economic Gains from Early Breast Cancer and Curative Treatment: A Case Study in Human Epidermal Growth Factor Receptor (HER-2) Positive Targeted Therapies. Oncology and therapy 12 (2) (2024)
Svenn Alexander Kommandantvold, Annabelle Lemenuel-Diot, Chris Skedgel, Richard Pitman, Peter Rouse, Hassan Zaraket, Hao Zhou, Marie-Helene Blanchet Zumofen
A cost-effectiveness analysis of reduced viral transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and pandemic influenza management in the United Kingdom. Expert review of pharmacoeconomics & outcomes research (2024)
Jesse A Sussell, David J Press, Svenn Alexander Kommandantvold, Eunice Kim, Yolande du Toit, Anita Fung
Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States. Advances in therapy (2023)